Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Affiliations

• ¹ Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands.
• ² Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
• ³ Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany.
• ⁴ Haukeland University Hospital, Bergen, Norway.
• ⁵ Dutch-Belgian Hemato-Oncology Cooperative Group Data Center-Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ⁶ Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania.
• ⁷ Skanes University Hospital, Lund, Sweden.
• ⁸ University Hospital Gasthuisberg, Leuven, Belgium.
• ⁹ University Hospital, Zurich, Switzerland; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland.
• ¹⁰ Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital; University Hospital, Bern, Switzerland.
• ¹¹ Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; University Hospital, Basel, Switzerland.
• ¹² Helsinki University Hospital Cancer Center, Helsinki, Finland.
• ¹³ Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ¹⁴ Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands. j.cloos@amsterdamumc.nl.